Following Telehealth Company’s Fallout, Global Leader in Evidence-based Objective ADHD Testing Technology Seeks to Ease Diagnosis Concerns of Former Done Patients

In response to the recent arrests of Done founder Ruthia He and clinical leader David Brody for the company’s alleged stimulant prescription practices, Qbtech, the global leader in objective ADHD testing, announced today it is waiving testing fees for former Done patients. The free objective tests are designed to serve as a safeguard for patients seeking a re-assessment to validate an ADHD diagnosis completed by a Done virtual provider.

The allegations against Done’s executives put telehealth practices and ADHD treatment under further scrutiny at a critical time for U.S. health policy. As the DEA deliberates on telehealth prescribing policies, this case highlights the worst possible outcomes of telehealth care, potentially jeopardizing access to care for millions of patients across the U.S.

“These purported prescribing practices by Done exacerbate the critical need for quality measures in ADHD to assure robust diagnostic decisions and effective treatment monitoring,” said Carl Reuterskiold, CEO of Qbtech. “We’re facing a global shortage of qualified clinicians to meet the growing demand for patients seeking help, not to mention the medication shortage that has been ongoing for over two years. Without objective quality measures, supportive policies and vigorous processes, the promising potential of telehealth ADHD care and other innovative care models is under great threat.”

Objective data is necessary to deliver first-rate care and address provider shortages while ensuring a scalable clinical process that is well-documented, unbiased, and effective for ongoing treatment monitoring. Advanced evidence-based technology to support standard subjective assessments for ADHD has been proven in several studies to deliver the same high-quality results across all care settings. More than 12,000 clinicians globally use this type of measurable data to inform their decisions, adding a level of confidence for clinicians and assurance for patients.

“We have been focused on high-quality tests and processes in ADHD care for more than 20 years, having administered over 1 million patients tested, 100,000 of whom were supported via telehealth,” added Carl Reuterskiold. “The CDC estimates that as many as 50,000 former Done patients may face disruption to their care, with many needing to seek re-evaluation from a new provider to continue treatment. By offering free tests to providers tasked with re-evaluating diagnoses, we aim to provide these patients with evidence-based measurements to ensure an accurate re-assessment of their symptoms.”

As a testament to Qbtech’s mission to improve the lives of those with ADHD, the company is offering one free test per patient through Sept. 30, 2024. Test credits will be applied to providers’ Qbtech customer accounts to use when re-evaluating Done patients. For additional details on the program and to register, visit https://www.qbtech.com/let-us-support-you-in-helping-former-done-patients/.

About Qbtech

Founded in 2002, Qbtech is a privately-owned Swedish company that has developed leading solutions and products for improving the identification, diagnosis, treatment, and follow-up of patients living with ADHD. Qbtech has operations in 14 countries and has offices in Stockholm, Houston, and London. Qbtech is an award-winning company recognized for its innovation, most recently winning the 2022 HSJ Partnership Award for the ‘Best Mental Health Partnership with the NHS.’ For more information about Qbtech, visit www.qbtech.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240715327982/en/